BRKB

478.83

-0.32%↓

BRKA.US

718,050

-0.31%↓

JPM

292.14

+0.76%↑

V

303.99

-0.07%↓

MA

499.05

-0.32%↓

BRKB

478.83

-0.32%↓

BRKA.US

718,050

-0.31%↓

JPM

292.14

+0.76%↑

V

303.99

-0.07%↓

MA

499.05

-0.32%↓

BRKB

478.83

-0.32%↓

BRKA.US

718,050

-0.31%↓

JPM

292.14

+0.76%↑

V

303.99

-0.07%↓

MA

499.05

-0.32%↓

BRKB

478.83

-0.32%↓

BRKA.US

718,050

-0.31%↓

JPM

292.14

+0.76%↑

V

303.99

-0.07%↓

MA

499.05

-0.32%↓

BRKB

478.83

-0.32%↓

BRKA.US

718,050

-0.31%↓

JPM

292.14

+0.76%↑

V

303.99

-0.07%↓

MA

499.05

-0.32%↓

Search

PennantPark Floating Rate Capital Ltd

Закрыт

8.05 -1.71

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

7.99

Макс.

8.16

Ключевые показатели

By Trading Economics

Доход

-21M

-3.6M

Продажи

-21M

26M

P/E

Средняя по отрасли

24.515

54.048

Прибыль на акцию

0.27

Дивидендная доходность

15.34

Рентабельность продаж

-13.888

EBITDA

-23M

-4M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+27.01% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

15.34%

4.84%

Следующий отчет о доходах

11 мая 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-126M

803M

Предыдущая цена открытия

9.76

Предыдущая цена закрытия

8.05

PennantPark Floating Rate Capital Ltd График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 мар. 2026 г., 23:47 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 мар. 2026 г., 22:55 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 мар. 2026 г., 21:51 UTC

Приобретения, слияния, поглощения

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 мар. 2026 г., 23:59 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

23 мар. 2026 г., 23:59 UTC

Обсуждения рынка

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 мар. 2026 г., 23:50 UTC

Обсуждения рынка

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 мар. 2026 г., 23:37 UTC

Обсуждения рынка

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 мар. 2026 г., 22:42 UTC

Обсуждения рынка
Главные новостные события

Global Equities Roundup: Market Talk

23 мар. 2026 г., 22:42 UTC

Обсуждения рынка
Главные новостные события

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 мар. 2026 г., 22:40 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 мар. 2026 г., 22:23 UTC

Обсуждения рынка

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 мар. 2026 г., 22:22 UTC

Приобретения, слияния, поглощения

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 мар. 2026 г., 22:21 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 мар. 2026 г., 22:21 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 мар. 2026 г., 22:20 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 мар. 2026 г., 22:20 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 мар. 2026 г., 22:19 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 мар. 2026 г., 22:19 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 мар. 2026 г., 22:18 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 мар. 2026 г., 22:15 UTC

Приобретения, слияния, поглощения

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 мар. 2026 г., 22:08 UTC

Обсуждения рынка

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 мар. 2026 г., 21:42 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

23 мар. 2026 г., 21:42 UTC

Обсуждения рынка

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 мар. 2026 г., 21:32 UTC

Отчет

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 мар. 2026 г., 21:32 UTC

Отчет

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 мар. 2026 г., 21:32 UTC

Отчет

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 мар. 2026 г., 21:10 UTC

Главные новостные события

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 мар. 2026 г., 20:50 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

23 мар. 2026 г., 20:50 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

23 мар. 2026 г., 20:50 UTC

Обсуждения рынка
Отчет
Главные новостные события

Basic Materials Roundup: Market Talk

Сравнение c конкурентами

Изменение цены

PennantPark Floating Rate Capital Ltd Прогноз

Целевая цена

By TipRanks

27.01% рост

Прогноз на 12 месяцев

Средняя 10.25 USD  27.01%

Максимум 10.5 USD

Минимум 10 USD

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для PennantPark Floating Rate Capital Ltd  на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

3 ratings

3

Покупка

0

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании PennantPark Floating Rate Capital Ltd

PennantPark Floating Rate Capital Ltd. is a business development company. It seeks to make secondary direct, debt, equity, and loan investments. The fund seeks to invest through floating rate loans in private or thinly traded or small market-cap, public middle market companies. It primarily invests in the United States and to a limited extent non-U.S. companies. The fund typically invests between $2 million and $20 million. The fund also invests in equity securities, such as preferred stock, common stock, warrants or options received in connection with debt investments or through direct investments. It primarily invests between $10 million and $50 million in investments in senior secured loans and mezzanine debt. It seeks to invest in companies not rated by national rating agencies. The companies if rated would be between BB and CCC under the Standard & Poor's system. The fund invests 30% is invested in non-qualifying assets like investments in public companies whose securities are not thinly traded or do not have a market capitalization of less than $250 million, securities of middle-market companies located outside of the United States, high-yield bonds, distressed debt, private equity, securities of public companies that are not thinly traded, and investment companies as defined in the 1940 Act. Under normal conditions, the fund expects atleast 80 percent of its net assets plus any borrowings for investment purposes to be invested in Floating Rate Loans and investments with similar economic characteristics, including cash equivalents invested in money market funds. It expects to represent 65 percent of its portfolio through senior secured loans. In case of floating rate loans, it holds investments for a period of three to ten years.
help-icon Live chat